FINWIRES · TerminalLIVE
FINWIRES

Oracle On Path to Become 'Foundational' AI Infrastructure Provider, CapEx Concerns Misread, Wedbush Says

-- Oracle (ORCL) is on track to become a "foundational" infrastructure provider for the artificial intelligence revolution, with investors misreading the risks tied to its capital spending, Wedbush Securities said in a Friday client note.

The brokerage initiated its coverage on the cloud computing company with an outperform rating on the stock and a 12-month price target of $225. Shares of the firm were up 1.6% in the most recent premarket activity, having lost 9.6% so far this year.

Wedbush believes Oracle is in the early stages of a backlog-driven AI expansion, with its cloud infrastructure service having a key advantage over complex legacy cloud platforms. The company's strategy to integrate proprietary enterprise data with strong AI models is also creating real-world business value, according to the brokerage.

"We believe Oracle is in the early innings of a significant repositioning as it executes on this generational opportunity," Wedbush analysts, including Dan Ives, wrote in the note. "The vision is supported by partnerships with AI leaders like OpenAI and Nvidia (NVDA), and endeavors like the Stargate project."

The downside case on Oracle centers on its capital expenditures and negative free cash flow, but this view is "backward-looking" and "fails to appreciate the scale of contracted demand underpinning the investment," Wedbush said.

Oracle's remaining performance obligations have increased to $553 billion, driving its capital expenditure-to-RPO ratio to about 9%, compared with the group average of roughly 45.6%, Wedbush said. "This demonstrates that spending is not speculative but is deployed to service a massive backlog," according to Ives.

In February, Oracle disclosed plans to raise between $45 billion and $50 billion this year to expand its cloud infrastructure business through a combination of debt and equity financing. The company said at the time that it would raise funds to build additional capacity and meet the contracted demand from its largest cloud customers, including Nvidia.

"As Oracle continues to convert its backlog into revenue, we expect the market narrative to shift from focusing on capex risk to the durable, long-term growth story that is unfolding," Ives wrote in the note.

相關文章

Insider Trading

根據最近提交給美國證券交易委員會(SEC)的文件顯示,高盛集團內部人士出售了價值1,044,782美元的股票。

首席風險長 Alex S Golten 於 2026 年 4 月 23 日出售了 1,116 股高盛集團 (GS) 股票,套現 1,044,782 美元。根據向美國證券交易委員會 (SEC) 提交的 4 號表格文件,Golten 共持有該公司 2,578 股普通股,其中 2,578 股為直接持有。 SEC 文件連結: https://www.sec.gov/Archives/edgar/data/886982/000205084926000015/xslF345X05/wk-form4_1777061036.xml

$GS
Research

研究報告:CFRA 將 West Pharmaceutical Services, Inc. 的評級從「持有」上調至「買入」。

獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點總結如下:我們12個月的目標價為350美元,高於先前的267美元,相當於我們2026年每股收益預期的41倍(上調0.63美元至8.53美元;2027年每股收益預期上調0.61美元至9.42美元),接近WSTST3五年遠期平均市盈率4220227261美元),822967年每股收益。我們的估值反映了我們對高價值產品(HVP)業務強勁表現、GLP-1彈性體銷售市場成長以及公司穩健的資產負債表(淨負債為負)的預期。我們預期新藥研發將支撐HVP業務,因為生物製劑在2026年第一季約佔銷售額的42%。此外,GLP-1藥物的需求可能成為注射器銷售的新催化劑。 WST與諾和諾德簽訂了一份多年期合同,為其所有GLP-1初級包裝彈性體需求提供供應。 GLP-1彈性體佔2026年第一季銷售額的10%。加上West Vantage業務部門的銷售額,GLP-1相關業務在該季度佔總淨銷售額的18%。我們認為,醫療器材製造領域附件1法規的更新也為HVP帶來了利好,這得益於WST現有組件的品質升級項目。

$WST
Australia

產業動態:能源股午後走軟

能源股週五下午稍晚下跌,紐約證券交易所能源板塊指數下跌0.7%,道富能源精選產業SPDR ETF(XLE)下跌0.2%。 費城石油服務類股指數上漲1.8%,道瓊美國公用事業指數上漲0.1%。 西德州中質原油下跌1.2%至每桶94.68美元,全球基準布蘭特原油上漲0.5%至每桶105.64美元。亨利樞紐天然氣期貨下跌3.7%至每百萬英熱單位2.52美元。 在公司新聞方面,道達爾能源(TTE)為其位於哈薩克東南部的米爾尼陸上風電和電池儲能係統專案獲得了融資。該公司股價下跌0.7%。 X-Energy(XE)股票在納斯達克上市首日飆升27%。 斯洛伐克集團 (SLB) 公佈的第一季業績喜憂參半,反映出中東衝突帶來的不利影響。儘管營收超出預期,但獲利下滑,股價仍上漲 2.8%。 根據彭博社報道,西班牙燃料批發商 Hatta Energy 向歐盟委員會提交投訴,指控英國石油公司 (BP) 和雷普索爾公司有反競爭行為。 BP 股價下跌 0.4%。

$BP$SLB$TTE$XE